Edwards Lifesciences Corp banner

Edwards Lifesciences Corp
F:EWL

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
F:EWL
Watchlist
Price: 74.84 EUR -1.01% Market Closed
Market Cap: €45.1B

Wall St Price Targets

EWL Price Targets Summary
Edwards Lifesciences Corp

Wall Street analysts forecast EWL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EWL is 84.61 EUR with a low forecast of 74.17 EUR and a high forecast of 99.78 EUR.

Lowest Forecast
Price Target
74.17 EUR
1% Downside
Average Forecast
Price Target
84.61 EUR
13% Upside
Highest Forecast
Price Target
99.78 EUR
33% Upside
Edwards Lifesciences Corp Competitors:
Price Targets
PXS
Pyxis Tankers Inc
130% Upside

Revenue
Forecast

9% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss
9% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 11%.

Gross Profit
Forecast

10% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
10% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 3 years is 12%.

Operating Income
Forecast

11% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss
11% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 15%.

Pre-Tax Income
Forecast

10% / Year
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss
10% / Year
Past Growth
28% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 28%.

Net Income
Forecast

11% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
11% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 27%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is EWL's stock price target?
Price Target
84.61 EUR

According to Wall Street analysts, the average 1-year price target for EWL is 84.61 EUR with a low forecast of 74.17 EUR and a high forecast of 99.78 EUR.

What is the Revenue forecast for Edwards Lifesciences Corp?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 11%.

What is the Gross Profit forecast for Edwards Lifesciences Corp?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 3 years is 12%.

What is the Operating Income forecast for Edwards Lifesciences Corp?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 15%.

What is the Pre-Tax Income forecast for Edwards Lifesciences Corp?
Projected CAGR
28%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 28%.

What is the Net Income forecast for Edwards Lifesciences Corp?
Projected CAGR
27%

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 27%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett